amiodarone has been researched along with rivaroxaban in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (64.71) | 24.3611 |
| 2020's | 6 (35.29) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Lip, GY; Shantsila, A | 1 |
| Ahmad, Y; Lip, GY | 1 |
| Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Hellkamp, AS; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Passman, R; Patel, MR; Piccini, JP; Singer, DE; Steinberg, BA | 1 |
| Guo, X; Li, L; Tang, B; Xu, G; Zhang, Y; Zhou, X | 1 |
| Elikowski, W; Małek, M; Skowroński, M; Skrzywanek, P; Wróblewski, D; Zawilska, K | 1 |
| Arceluz, M; Escobar, C; López-Sendón, JL; Merino, JL; Montes de Oca, R; Mori, R | 1 |
| Göndör, G; Stöllberger, C | 1 |
| Chan, ECY; Cheong, EJY; Goh, JJN; Hong, Y; Kojodjojo, P | 1 |
| Jetter, A; Kaserer, A; Schedler, A; Seifert, B; Spahn, DR; Stein, P; Studt, JD | 1 |
| Dorff, MH; Falskov, B; Jensen, EA; Skov, K | 1 |
| Chen, CY; Chiou, WR; Chuang, JY; Huang, CC; Kuo, JY; Lee, YH; Liao, FC; Lin, PL; Liu, LY; Su, MI; Tsai, CT; Wu, YJ | 1 |
| Chan, ECY; Chin, SY; Tan, HL; Tang, LWT | 1 |
| Chan, ECY; Cheong, EJY; Kojodjojo, P; Wang, Z | 1 |
| Cai, S; Liu, W; Pan, Y; Sun, P; Wang, M; Zhang, P; Zhao, Q | 1 |
| Chung, CP; Daugherty, JR; Dickson, AL; Dupont, WD; Hung, AM; Murray, KT; Ray, WA; Smalley, W; Stein, CM; Zimmerman, E | 1 |
1 review(s) available for amiodarone and rivaroxaban
| Article | Year |
|---|---|
Stroke prevention in atrial fibrillation: concepts and controversies.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Dronedarone; Drug Design; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
1 trial(s) available for amiodarone and rivaroxaban
| Article | Year |
|---|---|
Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Female; Humans; Intention to Treat Analysis; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Treatment Outcome | 2014 |
15 other study(ies) available for amiodarone and rivaroxaban
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Highlights of the American Heart Association Scientific Sessions 2011: a focus on ATLAS-TIMI 51, TRACER and PALLAS.
Topics: Acute Coronary Syndrome; American Heart Association; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Fibrinolytic Agents; Humans; Lactones; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome; United States; Venous Thromboembolism | 2012 |
[Update on current care guidelines: atrial fibrillation].
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dronedarone; Finland; Humans; Morpholines; Practice Guidelines as Topic; Rivaroxaban; Thiophenes; Warfarin | 2012 |
[The clinical analysis of atrial fibrillation of 1 310 in patients in Urumqi of China].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; China; Comorbidity; Diabetes Mellitus; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Humans; Hypertension; Incidence; Inpatients; Male; Morpholines; Retrospective Studies; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2014 |
[Hemoptysis during concomitant treatment with rivaroxaban and amiodarone in a patient with a history of pulmonary disease].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bronchiectasis; Drug Therapy, Combination; Factor Xa Inhibitors; Hemoptysis; Humans; Male; Radiography; Rivaroxaban; Venous Thromboembolism | 2015 |
Concomitant Rivaroxaban and Dronedarone Administration in Patients With Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, Drug; Dronedarone; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Rivaroxaban; Stroke; Treatment Outcome | 2017 |
Pulmonary embolism four days after interruption of therapy with rivaroxaban.
Topics: Administration, Oral; Amiodarone; Atrial Fibrillation; Drug Administration Schedule; Drug Therapy, Combination; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Parotid Gland; Perioperative Care; Phenprocoumon; Postoperative Complications; Pulmonary Embolism; Rivaroxaban | 2017 |
Rivaroxaban With and Without Amiodarone in Renal Impairment.
Topics: Adult; Aged; Amiodarone; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Male; Middle Aged; Renal Insufficiency; Retrospective Studies; Rivaroxaban; Vasodilator Agents; Young Adult | 2018 |
Risk Factors for Higher-than-Expected Residual Rivaroxaban Plasma Concentrations in Real-Life Patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Blood Coagulation; Drug Administration Schedule; Drug Interactions; Drug Monitoring; Factor Xa Inhibitors; Female; Glomerular Filtration Rate; Half-Life; Humans; Kidney; Kidney Diseases; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Polypharmacy; Preoperative Care; Retrospective Studies; Risk Factors; Rivaroxaban; Switzerland | 2018 |
Supratheraputic rivaroxaban levels: A persistent drug-drug interaction after discontinuation of amiodarone.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Cytochrome P-450 CYP3A; Drug Interactions; Female; Humans; International Normalized Ratio; Rivaroxaban | 2020 |
Safety and Effectiveness of Rivaroxaban in Combination with Various Antiarrhythmic Drugs in Patients with Non-Permanent Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiovascular Diseases; Dronedarone; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Propafenone; Retrospective Studies; Rivaroxaban; Taiwan | 2021 |
Investigation of the arcane inhibition of human organic anion transporter 3 by benzofuran antiarrhythmic agents.
Topics: Amiodarone; Anti-Arrhythmia Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Atrial Fibrillation; Benzofurans; Cell Line; Dronedarone; Drug Interactions; HEK293 Cells; Humans; Organic Anion Transporters, Sodium-Independent; Rivaroxaban | 2021 |
Model-Based Risk Prediction of Rivaroxaban with Amiodarone for Moderate Renal Impaired Elderly Population.
Topics: Aged; Amiodarone; Hemorrhage; Humans; Kidney; Renal Insufficiency; Rivaroxaban | 2023 |
Comparison of co-administration of amiodarone and rivaroxaban to co-administration of dronedarone and rivaroxaban for hemorrhage risks after atrial fibrillation ablation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Dronedarone; Hemorrhage; Humans; Rivaroxaban | 2022 |
Risk for Bleeding-Related Hospitalizations During Use of Amiodarone With Apixaban or Rivaroxaban in Patients With Atrial Fibrillation : A Retrospective Cohort Study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Flecainide; Hemorrhage; Hospitalization; Humans; Ischemic Stroke; Male; Medicare; Retrospective Studies; Rivaroxaban; Sotalol; Stroke; United States | 2023 |